As of May 2014, Daiichi Sankyo, Inc. is estimated to have a market cap of $11.64 billion.the question is what would a fair price be.
Welchol will be a gone. Effient is a loser. The HTN family is screwed with generic valsartan and the other generic ARBs poised to control the ARB class. Oncology...yeah, right. Savaysa...probably worth $7 billion to $9 billion. Price for DSI: $9.4 billion.
Don't get your panties so knotted up, relax. Do your job and stop speculating on our future. Control your present and just do your flicking job.